Iovance Biotherapeutics, Inc.IOVANASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank44
5Y CAGR+34.4%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
+34.4%/yr
Long-term compound
Percentile
P44
Within normal range
vs 5Y Ago
4.4x
Strong expansion
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 4.60% |
| Q3 2025 | -8.34% |
| Q2 2025 | -14.17% |
| Q1 2025 | 3.35% |
| Q4 2024 | 7.46% |
| Q3 2024 | 15.69% |
| Q2 2024 | 30.90% |
| Q1 2024 | -12.65% |
| Q4 2023 | 10.90% |
| Q3 2023 | 22.97% |
| Q2 2023 | -22.03% |
| Q1 2023 | 6.27% |
| Q4 2022 | -5.13% |
| Q3 2022 | 5.94% |
| Q2 2022 | 12.45% |
| Q1 2022 | -1.83% |
| Q4 2021 | 14.18% |
| Q3 2021 | 8.18% |
| Q2 2021 | -1.60% |
| Q1 2021 | 22.00% |
| Q4 2020 | 1.05% |
| Q3 2020 | 10.89% |
| Q2 2020 | 3.57% |
| Q1 2020 | 27.47% |
| Q4 2019 | 8.41% |
| Q3 2019 | -7.71% |
| Q2 2019 | 19.67% |
| Q1 2019 | 20.68% |
| Q4 2018 | 5.79% |
| Q3 2018 | 4.19% |
| Q2 2018 | -1.98% |
| Q1 2018 | 29.58% |
| Q4 2017 | 17.10% |
| Q3 2017 | 16.85% |
| Q2 2017 | -7.77% |
| Q1 2017 | -16.24% |
| Q4 2016 | -51.56% |
| Q3 2016 | 44.52% |
| Q2 2016 | 157.77% |
| Q1 2016 | -28.24% |